Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC

(2020) Chao Zhang et al.   Journal of Thoracic Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

(2020) Ana Ortega-Franco et al.   Translational Lung Cancer Research

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

(2019) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

1484PDFinal PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

(2019) T S K Mok et al.   ANNALS OF ONCOLOGY

Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement

(2018) Chao Zhang et al.   Journal of Thoracic Oncology

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

(2015) Wenzhao Zhong et al.   Journal of Hematology & Oncology

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

(2011) N. A. Rizvi et al.   CLINICAL CANCER RESEARCH